Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353287 | 0.85 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL12256527 | 0.82 | NPC1 (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL6344078 | 0.81 | KDM4E (0.52) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL3122943 | 0.76 | L3MBTL1 (0.49) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL17061216 | 0.73 | PTGDR2 (0.44) | SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL12768178 | 0.72 | SMN1; SMN2 (0.48) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL23245482 | 0.70 | L3MBTL1 (0.44) | KDM4ESMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL18524121 | 0.70 | SMN1; SMN2 (0.46) | SMN1; SMN2GAA | |
| SCHEMBL28001848 | 0.69 | TRPV1 (0.46) | CYP2D6 | |
| SCHEMBL28001846 | 0.69 | AKR1B1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| CN-110088120-A | inhibitors of transglutaminase | 策迪拉有限公司 | 2019-08-02 | — | — | CN | disclosed |
| EP-3405477-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-11-28 | — | — | EP | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-2334684-B1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-2334684-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010026214-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CNR1, CNR2, CHRM5 | KDM4E 1905/4885SMN1; SMN2 764/4885ALDH1A1 956/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | KDM4E 911/4885SMN1; SMN2 3418/4885ALDH1A1 1469/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | KDM4E 911/4885SMN1; SMN2 3418/4885ALDH1A1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.